BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 33507028)

  • 1. Immunotherapy in cholangiocarcinoma.
    Al-Rajabi R; Sun W
    Curr Opin Gastroenterol; 2021 Mar; 37(2):105-111. PubMed ID: 33507028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in Biliary Tract Cancers: Where Are We?
    Kalyan A; Khosla H; Kim RD
    Curr Oncol Rep; 2022 Dec; 24(12):1821-1828. PubMed ID: 36192517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
    Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
    Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunology and immunotherapy of cholangiocarcinoma.
    Greten TF; Schwabe R; Bardeesy N; Ma L; Goyal L; Kelley RK; Wang XW
    Nat Rev Gastroenterol Hepatol; 2023 Jun; 20(6):349-365. PubMed ID: 36697706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers.
    Chen R; Zheng D; Li Q; Xu S; Ye C; Jiang Q; Yan F; Jia Y; Zhang X; Ruan J
    Cancer Lett; 2022 Oct; 546():215853. PubMed ID: 35921970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in immunotherapy for biliary tract cancers.
    Zhao Y; Yang M; Feng J; Wang X; Liu Y
    Chin Med J (Engl); 2024 Mar; 137(5):524-532. PubMed ID: 37646139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors and combinations with other agents in cholangiocarcinoma.
    Skouteris N; Papageorgiou G; Fioretzaki R; Schizas D; Kykalos S; Tolia M; Charalampakis N
    Immunotherapy; 2023 May; 15(7):487-502. PubMed ID: 36876442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The state of therapy modalities in clinic for biliary tract cancer.
    Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
    Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Targeted Immunotherapy for Hepatobiliary Cancers.
    Ruff SM; Shannon AH; Pawlik TM
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current approaches to the diagnosis and treatment of cholangiocarcinoma.
    Reddy SB; Patel T
    Curr Gastroenterol Rep; 2006 Feb; 8(1):30-7. PubMed ID: 16510032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies.
    Argemi J; Ponz-Sarvise M; Sangro B
    Adv Cancer Res; 2022; 156():367-413. PubMed ID: 35961706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advance in immunotherapy on biliary tract cancers].
    Liu LG; Zhang YJ; Wang XA; Liu YB
    Zhonghua Wai Ke Za Zhi; 2021 Feb; 59(2):156-160. PubMed ID: 33378809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case Report: A novel mixture of dose-fractioned radiation and immunotherapy for treatment of cholangiocarcinoma.
    Wang N; Wang L; Huang A; Han J; Cao T; Mei X; Yao J; Xiao Y; Ma H
    Front Immunol; 2023; 14():1273962. PubMed ID: 38162668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
    Rimassa L; Personeni N; Aghemo A; Lleo A
    J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies.
    Yu X; Zhu L; Wang T; Chen J
    Front Immunol; 2023; 14():1037945. PubMed ID: 37138880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances and considerations in the use of immunotherapies for primary hepato-biliary malignancies.
    Gorji L; Brown ZJ; Pawlik TM
    Surg Oncol; 2024 Feb; 52():102031. PubMed ID: 38128340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
    Zhang Q; Lou Y; Bai XL; Liang TB
    World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future directions in the treatment of cholangiocarcinoma.
    Zhu AX
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy and targeted therapy for cholangiocarcinoma: Artificial intelligence research in imaging.
    Liu J; Shu J
    Crit Rev Oncol Hematol; 2024 Feb; 194():104235. PubMed ID: 38220125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholangiocarcinoma - novel biological insights and therapeutic strategies.
    Ilyas SI; Affo S; Goyal L; Lamarca A; Sapisochin G; Yang JD; Gores GJ
    Nat Rev Clin Oncol; 2023 Jul; 20(7):470-486. PubMed ID: 37188899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.